Compare AbCellera Biologics Inc (ABCL) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while First Trust NASDAQ 100 Technology Index Fund trades at $312.09. Which is the better fit depends on your goals.
| ABCL | QTEC | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $8.12 | $335.74 |
52-Week Low | $2.78 | $207.03 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
QTEC trades at $320.77, up 1.84% with neutral technical signals and bullish moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, recently hitting 52-week highs. Support levels cluster around $313-318 while resistance sits at $324-329. Recent news highlights QTEC's role in tech sector exposure amid AI and chip stock momentum.
The ETF's equal-weight approach diversifies tech sector risk, though concentrated tech exposure remains sensitive to sector volatility. Current technical positioning suggests consolidation near pivot points, with institutional interest balanced by valuation concerns in overheated AI segments. Key risks include sector rotation and macroeconomic pressure on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
